ProfileGDS5678 / 1428583_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 81% 76% 80% 82% 77% 80% 79% 81% 78% 80% 78% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8219982
GSM967853U87-EV human glioblastoma xenograft - Control 25.7792881
GSM967854U87-EV human glioblastoma xenograft - Control 35.8571881
GSM967855U87-EV human glioblastoma xenograft - Control 45.2965576
GSM967856U87-EV human glioblastoma xenograft - Control 55.7619280
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.7441482
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.0825877
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.6036480
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.5298879
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8695381
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3907378
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.6578180
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.3286478
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6944880